- CureVac (CVAC -3.3%) in collaboration with Tesla (TSLA -2.9%) are developing an mRNA printer that with the help of required reagents could develop mRNA medicines on a computer, tailored to a particular patient’s requirement.
- The drug printer is about the size of a regular car, and it could ‘print’ the medicine on-site after sourcing the reagents via a courier and downloading the prescription for the required medicine over the internet.
- “The printers can be placed in pharmacies and doctors' offices around the world,” Ingmar Hoerr, the founder, and CEO of CureVac said.
- “There is still a lot to optimize,” Hoerr added. It could be several years before the device is ready for mass production.
- In August, it was reported that CureVac was working with Tesla Grohmann Automation, a unit of the electric car maker, to develop RNA printers to help manufacture its messenger-RNA-based vaccine candidate.